2024-10-30 2025-10-31 false No description of principal activity Acting Office - Tax and Accounts 1.0 16050502 bus:FullAccounts 2024-10-30 2025-10-31 16050502 bus:FRS102 2024-10-30 2025-10-31 16050502 bus:AuditExempt-NoAccountantsReport 2024-10-30 2025-10-31 16050502 bus:SmallCompaniesRegimeForAccounts 2024-10-30 2025-10-31 16050502 bus:PrivateLimitedCompanyLtd 2024-10-30 2025-10-31 16050502 2024-10-30 2025-10-31 16050502 2025-10-31 16050502 bus:RegisteredOffice 2024-10-30 2025-10-31 16050502 core:WithinOneYear 2025-10-31 16050502 core:AfterOneYear 2025-10-31 16050502 2023-10-30 16050502 bus:Director1 2024-10-30 2025-10-31 16050502 bus:Director1 2025-10-31 16050502 bus:Director2 2024-10-30 2025-10-31 16050502 bus:Director2 2025-10-31 16050502 bus:Director3 2024-10-30 2025-10-31 16050502 bus:Director3 2025-10-31 16050502 bus:Director4 2024-10-30 2025-10-31 16050502 bus:Director4 2025-10-31 16050502 bus:CompanySecretary1 2024-10-30 2025-10-31 16050502 bus:LeadAgentIfApplicable 2024-10-30 2025-10-31 16050502 2024-10-29 16050502 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-10-30 2025-10-31 16050502 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-10-31 16050502 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-10-29 16050502 core:CostValuation core:Non-currentFinancialInstruments 2025-10-31 16050502 core:CostValuation core:Non-currentFinancialInstruments 2024-10-29 16050502 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2025-10-31 16050502 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2025-10-31 16050502 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-10-31 16050502 core:ShareProfitOrLossIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-10-31 16050502 core:ProvisionsForImpairmentInvestments core:Non-currentFinancialInstruments 2025-10-31 16050502 core:ImpairmentReversalProvisionsForImpairmentInvestments core:Non-currentFinancialInstruments 2025-10-31 16050502 core:ForeignExchangeDifferencesIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-10-31 16050502 core:TransfersIntoOrOutInvestmentsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-10-31 16050502 core:TransfersBetweenInvestmentClassesIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-10-31 16050502 core:Non-currentFinancialInstruments 2025-10-31 16050502 core:Non-currentFinancialInstruments 2024-10-29 16050502 core:ShareCapital 2025-10-31 16050502 core:RetainedEarningsAccumulatedLosses 2025-10-31 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 16050502
England and Wales

 

 

 


Unaudited Financial Statements

for the period ended 31 October 2025

for

OPTECA LIMITED

 
 
Notes
 
2025
£
Fixed assets
Intangible fixed assets 2 25,635 
25,635 
Current assets
Debtors 3 398 
Cash at bank and in hand 176 
574 
Creditors: amount falling due within one year 4 (34,732)
Net current assets/(liabilities) (34,158)
 
Total assets less current liabilities (8,523)
Net assets/(liabilities) (8,523)
 

Capital and reserves
Called up share capital 100 
Profit and loss account 5 (8,623)
Shareholders fund (8,523)
 
For the period ended 31 October 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' Responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476 of the Companies Act 2006.
  2. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime of Part 15 of the Companies Act 2006.
Signed on behalf of the board of directors:


---------------------------------------------
Richard Philip Cowling
Director

Date approved: 24 July 2026
1
Statutory Information
Opteca Limited is a private limited company, limited by shares, domiciled in England and Wales, registration number 16050502, registration address 10 Venture Point, Stanney Mill Road, Chester, CH2 4NE, United Kingdom.

The presentation currency is £ sterling.
1.

Accounting Policies

Basis of accounting
The financial statements are prepared under the historical cost convention and in accordance with the FRS 102 Financial Reporting Standard for Smaller Entities (effective January 2016).
Website cost
Planning and operating costs for the company's website are charged to the profit and loss account as incurred.
Intangible assets
Intangible assets (including purchased goodwill and patents) are amortised at rates calculated to write off the assets on a straight line basis over their estimated useful economic lives. Impairment of intangible assets is only reviewed where circumstances indicate that the carrying value of an asset may not be fully recoverable.
Development expenditures
Research and development expenditure is charged to the profit and loss account in the period in which it is incurred. However, where the directors are satisfied as to the technical, commercial and financial viability of individual projects, development expenditure is deferred and amortised over [no_of_years] years during which the company is expected to benefit.
Cash and cash equivalents
Cash and cash equivalents are highly liquid investments and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.
Trade and other creditors
Short-term creditors are measured at the transaction price. The other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, unless the effect of discounting would be immaterial, in which case they are stated at cost.
Equity instruments
Equity instruments issued by the Company are recorded at the fair value of cash or other resources received or receivable, net of direct issue costs. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the Company.
2.

Intangible fixed assets

Cost or Valuation   Development costs   Total
    £   £
Additions   25,635    25,635 
At 31 October 2025   25,635    25,635 
3.

Debtors: amounts falling due within one year

2025
£
VAT 398 
398 
4.

Creditors: amount falling due within one year

2025
£
Neem Consulting -Creditors 14,320 
Oliver MacPherson 1,477 
Otectics 14,771 
Accrued expenses 479 
Other creditors 3,685 
34,732 
5.

Profit and loss account

  2025
£
Balance at 30 October 2024
Loss for the period (8,623)
Balance at 31 October 2025 (8,623)

6.

Average number of employees

Average number of employees during the period was 0.
2